Photobiomodulation with the Valeda light delivery system was authorized in November 2024, and we have been treating patients with it since summer 2025.It seems too simple to be true that we could shine a light in someone’s eyes for a few minutes nine t…
Q&A: Confronting gender gaps in research
International Women’s Day, dedicated to celebrating women’s social and political achievements and raising awareness of gender inequities, is observed every March 8.In recognition of the observance, Healio spoke with Louise P. King, MD, JD, a surgeon an…
VIDEO: Next-generation therapies, GLP-1s could be game changers in retinal diseases
WAIKOLOA, Hawaii — In this expert perspective from Retina 2026, Ehsan Rahimy, MD, a retina specialist at Palo Alto Medical Foundation, discussed promising advancements in the treatment of retinal diseases.Rahimy said there was a plethora of real-world …
National Vision Holdings, Inc. Reports Fourth Quarter and Fiscal 2025 Financial Results
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today reported its financial results for the fourth quarter and fiscal year ended January 3, 2026, and is providing its outlook for fiscal 2…
STAAR Surgical Issues Shareholder Letter
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued a Shareholder Letter on Tuesday, March 3 af…
STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the fourth quarter and fiscal…